애브비(AbbVie)가 TGF-β 활성화에 관여하는 GARP(glycoprotein A repetitions predominant) 타깃 항체 ‘리브모니플리맙(livmoniplimab, ABBV-151)’의 임상을 모두 중단하며, 파이프라인에서 삭제했습니다. 리브모니플리맙은 애브비가 지난 2016년 아젠엑스와 계약금 4000만달러를 포함해 총 6억8500만달러 규모로 라이선스 옵션딜을 체결한 에셋인데요. 이후 애브비는 지난 2018년 옵션을 행사하며 리브모니플리맙의 글로벌 권리를 들여왔었습니다. 애브비는 지난 2월 리브모니플리맙의 진행중인 임상 5건에서 간암 2/3상, 방광암 초기임상 등 임상 4건을 중단한 바 있는데요. 최근 애브비는 유일하게 남아있던 비소세포폐암(NSCLC) 임상2상도 중단했으며, 이번에 중단이유로 현재 사용가능한 표준…

Channel
바이오스펙테이터
@biospectatorT
On this record: Topic · Growth · Engagement · Posts · Citations · Telegram's recommendations · Cite this entry
5,851subscribers
-33 since we began measuring on 6 August 2026
Risers and fallers across the register · movement among entries of 3,162–10,000.
Register entry
| Telegram ID | -1001329038589 |
|---|---|
| Type | Channel |
| Username | @biospectatorT |
| Created | 3 May 2021 — measured — cross-checked against a third-party dataset (ext.tg_channel) |
| First recorded | 6 August 2026 |
| Last confirmed live | 9 November 2026 |
| Measurements held | 21 |
| Confirmed unchanged | 1 time, most recently 9 November 2026 |
| On Telegram | t.me/biospectatorT |
Topic
Science — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 12 September 2026 and assigned it the closest of 31 fixed categories, at 57% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and the other topics.
Growth
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 9 Nov 2026, 02:00 | 5,851 | -1 |
| 5 Nov 2026, 11:56 | 5,852 | -4 |
| 30 Oct 2026, 10:30 | 5,856 | +2 |
| 24 Oct 2026, 10:17 | 5,854 | -4 |
| 15 Oct 2026, 12:04 | 5,858 | +3 |
| 12 Oct 2026, 15:59 | 5,855 | -8 |
| 5 Oct 2026, 22:41 | 5,863 | -10 |
| 28 Sept 2026, 10:57 | 5,873 | -7 |
| 18 Sept 2026, 10:16 | 5,880 | +3 |
| 10 Sept 2026, 00:01 | 5,877 | -4 |
| 4 Sept 2026, 22:39 | 5,881 | +2 |
| 1 Sept 2026, 06:46 | 5,879 | -2 |
| 29 Aug 2026, 03:49 | 5,881 | +7 |
| 26 Aug 2026, 11:44 | 5,874 | +2 |
| 23 Aug 2026, 22:16 | 5,872 | +4 |
| 19 Aug 2026, 20:43 | 5,868 | -1 |
| 16 Aug 2026, 21:23 | 5,869 | +2 |
| 13 Aug 2026, 08:53 | 5,867 | -11 |
| 10 Aug 2026, 04:54 | 5,878 | -4 |
| 7 Aug 2026, 02:30 | 5,882 | first reading |
Engagement
71 posts held, back to 4 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 10 pages of Telegram’s post history, 20 posts per page.
- ERR · 30 days
- 10.6%
- avg views ÷ 5,851 subscribers
- Avg views / post
- 621
- 20 posts measured
- Reaction rate
- —
- this channel exposes no reaction counts
- Posts in window
- 20
- of 71 held
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.
| Window | Rolling 30 days · latest post in window 4 November 2026 |
|---|---|
| Posts held | 71 (4 August 2026 – 4 November 2026) |
| Views total | 12,417 |
| Reactions total | — |
| Forwards / comments | not exposed by the public surface — not measured, not estimated |
| Readings taken | 4 Nov 2026, 16:01 UTC |
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
Recent posts
Telegram’s own ‘edited’ marker: 0 of 20 posts held from the last 30 days (0%) carried it when this register last read them. The marker says a post was changed after publishing, not what it said before — this register holds the earlier wording only where an edit fell between two of its own reads (see the edit ledger and how it is measured).
루닛, 477억 규모 CB 발행 결정..”고금리 CB 대환“ 기존 연 8% 만기보장수익률 CB를 연 4%로 대환 ”재무부담 완화“ https://m.biospectator.com/view/news_view.php?varAtcId=30301
재미한인제약인협회(KASBP)가 창립 25주년을 맞아 신약의 진화와 미래 전망에 대한 주제로, 오는 13일부터 14일까지 양일간 가을 심포지엄을 개최합니다. 이번 KASBP 행사는 미국 뉴저지주 뉴어크 국제공항 인근 더블트리 바이 힐튼호텔(DoubleTree by Hilton Hotel)에서 ‘신약발굴과 개발 경쟁현황: 진화와 미래 전망(Drug discovery and development landscape: evolution and future horizons)’라는 주제로 열립니다. https://m.biospectator.com/view/news_view.php?varAtcId=30289
SK바팜, ’세노바메이트‘ 신규 적응증 ”FDA 허가신청“ ’세노바메이트‘ PGTC 적응증 추가 허가신청서(sNDA) 신청..계속해서 적응증, 연령, 제형 ’확장‘ https://m.biospectator.com/view/news_view.php?varAtcId=30297
티움, ’TGFβRI/VEGFR2‘ 두경부암 ”美패스트트랙 지정“ ’키트루다‘와 병용요법 두경부암 1차 치료 대상 https://m.biospectator.com/view/news_view.php?varAtcId=30298
애브비(Abbvie)는 중국 브리즈 파마슈티컬(Brise Pharmaceuticals)에서부터 편두통을 적응증으로 하는 전임상단계 에셋 2가지를 총 7억5700만달러 규모로 사들였습니다. 2년전 체결했던 계약에 따라 브리즈는 약물발굴을 담당하고, 애브비는 브리즈의 전임상단계 편두통 치료제 후보물질 2가지 프로그램에 대한 글로벌 개발 및 상업화 활동을 주도하게 되는데요. 브리즈는 애브비와 전임상단계 편두통 치료제 후보물질 2가지의 라이선스인(L/I) 계약을 체결했다고 밝혔습니다. 해당 계약은 지난 2024년 체결된 바 있으며, 브리즈는 이번에 체결 소식을 처음으로 공개한 것입니다. 계약에 따라 개발, 상업화, 규제승인 및 판매 마일스톤 등을 포함한 총 규모는 7억5700만달러이며, 매출에 따른 로열티는 별도입니다. 브리즈는 이같은 소식을 …
테바 파마슈티컬(Teva Pharmaceuticals)이 α-syn 저해제 ‘엠루솔민(emrusolmin, TEV-’286)’의 다계통위축증(MSA) 임상2상 개발을 중단합니다. 엠루솔민은 MSA의 주요 원인으로 알려진 독성 α-syn 응집체(oligomer) 형성을 억제하는 저분자화합물로, 테바는 지난 2021년 독일 모다그(MODAG GmbH)로부터 엠루솔민의 개발권리를 확보했고, 이후 혁신신약 사업확대를 위한 핵심 파이프라인 중 하나로 개발해왔습니다. 특히 MSA 환자를 대상으로 진행중인 TOPAS-MSA 임상2상은 오픈라벨연장(OLE) 임상을 제외하면 엠루솔민의 유일한 임상이었습니다. 이런 가운데 TOPAS-MSA 임상2상의 중간분석 결과 독립 데이터모니터링위원회(IDMC)는 임상을 지속하더라도 1차종결점을 달성할 가능성이 낮다고 …
지난 10월 비상장 바이오기업 투자는 2곳, 513억원으로 집계됐네요. 2곳 모두 신약개발 기업으로, 인공지능(AI) 바이오 플랫폼 기업 히츠(HITS)가 시리즈B에서 183억원을, 차세대 항체-약물접합체(ADC) 연구개발 바이오텍 트리오어(Trioar)가 시리즈C 라운드에서 330억원을 유치했습니다. 전달인 지난 9월에 비해서 건수는 4건에서 2건으로 줄었지만, 시리즈B 및 시리즈C 후기라운드 유치로 1.6배가량 늘어나며 다시 500억원 이상 규모를 달성했는데요. 까다로운 기준 등으로 투자대상 기업에 대한 허들은 높아지고, 대신 소수의 기업에 투자기관이 몰리면서 규모는 커지는 경향이 짙어지는 모습입니다. 상장사에서는 자금조달이 1건 있었으며, 웨어러블 AI 진단 모니터링 기업 씨어스(SEERS)는 1100억원 규모의 사모 전환사채(CB)…
독일 프레제니우스(Fresenius SE & Co. KGaA)는 중국 CDMO 우시바이오로직스(WuXi Biologics)와 최대 37개의 새로운 바이오시밀러를 개발하는 옵션딜을 체결했네요. 프레제니우스는 이번 옵션딜을 통해 향후 10년간 최대 37개의 바이오시밀러 후보물질에 대한 독점 접근권리를 확보하게 됐으며, 자사 바이오시밀러 포트폴리오가 기존 시판하고 있는 9개와 개발중인 20개를 합한 29개로부터 최대 66개까지 확대될 수 있습니다. 회사는 바이오시밀러 분야에서 공개된 개발 계약 중 최대규모라고 강조했습니다. 다만 자세한 계약금 및 마일스톤 규모 등은 공개하지 않았습니다. https://www.biospectator.com/news/view/30283
삼성에피스, 테바와 ’시밀러‘ 2종 美판매 ”4.2억弗 딜“ 삼성바이오에피스 美시판허가 ’자가면역질환 바이오시밀러 2종‘ 미국내 상업화 계약체결 https://m.biospectator.com/view/news_view.php?varAtcId=30291
HLB, ‘리보세라닙’ FDA 허가결정 내년 4월9일까지 FDA, Class2 분류 "본심사 착수" https://www.biospectator.com/news/view/30292
#바이오스펙테이터 #전일(11/03, TUE) #전체기사 ▶ AZ, 'AR분해제·STEAP2 TCE' 등 초기에셋 4개 "중단" https://www.biospectator.com/news/view/30260 ▶ 퍼스트바이오, SK바이오팜 등서 "100억 추가 투자유치" https://www.biospectator.com/news/view/30281 ▶ 삼성바이오, 글로벌 제약사와 3.24억弗 "CMO 계약" https://www.biospectator.com/news/view/30279 ▶ 갤럭스, 신용보증기금 ‘Pre-ICON’ 선정.."70억 보증지원" https://www.biospectator.com/news/view/30282 ▶ 밤부사, 나스닥 IPO 1.7억弗..면역 'IL-4RαxIL-31' 2b상 https://ww…
Showing the 12 most recent of 71 posts we hold for @biospectatorT. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Forward network
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
@pharmbiohana · 29,7895 posts[IV Research]
@IVResearch · 2,4792 posts[IV리서치] 제약/바이오
@buy_oh · 3062 postsBUY(!)BUY(!)바이오🤡DS 제약/바이오 김민정
@mnJeong_BIO · 8,0692 postsMJ의 Bio & Healthcare
@BarbarianBHC · 4,8681 post리가켐바이오 IR/PR 공식 채널
@SHIDGL · 9,8681 postYeouido Lab_여의도 톺아보기
@Yeouido_Lab · 43,4501 post간절한 투자스터디카페
@desperatestudycafe · 18,5101 post@오스코텍 IR/PR 공식 채널
@oscotecinc · 5901 post
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Appears in Telegram’s recommendations for other channels
The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.
@huhpharm · 24,264
Telegram ranks this channel #39 of 93 here — alongside 92 others — read 16 September 2026
This channel appears in 1 seed channel's Telegram-generated recommendation list in total. Each is Telegram’s list for THAT channel, not this one — see how this is measured.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 9 November 2026 — this entry's latest reading, not the date you are reading this.
“바이오스펙테이터” (@biospectatorT), 5,851 subscribers as measured 9 November 2026. Telegram Register, tgregister.com/channel/biospectatorT.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.